Answers are grounded in this paper and cite their sources.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established in clinical practice for the treatment of type 2 diabetes, and are approved and recommended for weight management in overweight or obesity. Gastrointestinal side effects are well known as the most common adverse effects of these agents and represent a potential barrier for use, particularly at higher doses. Drawing on both published evidence and our collective clinical experience, we aim to guide practitioners through managing these side effects with a view to optimizing therapeutic outcomes with GLP-1RAs.
No takes yet. Share an insight, caveat, or question.
Wharton et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: